ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report

Case Report: Compound heterozygous nonsense mutations in TRMT10A are associated with microcephaly, delayed development, and periventricular white matter hyperintensities

[version 1; peer review: 2 approved]
PUBLISHED 28 Sep 2015
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Rare diseases collection.

Abstract

Microcephaly is a fairly common feature observed in children with delayed development, defined as head circumference less than 2 standard deviations below the mean for age and gender. It may be the result of an acquired insult to the brain, such prenatal or perinatal brain injury (congenital infection or hypoxic ischemic encephalopathy), or be a part of a genetic syndrome. There are over 1000 conditions listed in OMIM (Online Mendelian Inheritance in Man) where microcephaly is a key finding; many of these are associated with specific somatic features and non-CNS anomalies. The term primary microcephaly is used when microcephaly and delayed development are the primary features, and they are not part of another recognized syndrome.
 
In this case report, we present the clinical features of siblings (brother and sister) with primary microcephaly and delayed development, and subtle dysmorphic features. Both children had brain MRI studies that showed periventricular and subcortical T2/FLAIR hyperintensities, without signs of white matter volume loss, and no parenchymal calcifications by CT scan. The family was enrolled in a research study for whole exome sequencing of probands and parents. Analysis of variants determined that the children were compound heterozygotes for nonsense mutations, c.277C>T (p.Arg93*) and c.397C>T (p.Arg133*), in the TRMT10A gene. Mutations in this gene have only recently been reported in children with microcephaly and early onset diabetes mellitus.
 
Our report adds to current knowledge of TRMT10A related neurodevelopmental disorders and demonstrates imaging findings suggestive of delayed or abnormal myelination of the white matter in this disorder. Accurate diagnosis through genomic testing, as in the children described here, allows for early detection and management of medical complications, such as diabetes mellitus.

Keywords

Primary microcephaly, Delayed development, Periventricular leukomalacia, White matter hyperintensities, Diabetes mellitus, TRMT10A, tRNA methyltransferase

Clinical summary

We present case histories of siblings (a sister and brother) born to healthy non-consanguineous parents, with microcephaly and delayed development.

Patient 1

The first patient is a 12 year old girl who was born at 39 weeks gestation weighing 4 lb 10 oz, without perinatal difficulties. She was healthy as an infant, except for recurrent ear infections, which were treated with tympanostomy tubes. Hypotonia was noted during infancy, but she reached her early motor milestones, including crawling and walking, at the normal ages. Speech delay and behavioral problems were noted by 4 years of age. There was no regression. Ophthalmological evaluation was normal. Physical exam at age 4.5 years showed microcephaly, low anterior hair line, deep set eyes with mild hypotelorism, shortened forehead, and her neurological exam was normal. Head circumference was 3.5 SD below the mean for age in girls. These features have remained constant at subsequent examinations.

MRI scan of the brain showed mild FLAIR/T2 hyperintensities in the periatrial white matter (Figure 1A); a CT scan did not show calcifications. Skeletal x-rays did not show any abnormality of her bones. Hearing tests, renal ultrasound, and echocardiogram were all normal. High resolution karyotype and array comparative genome hybridization (CGH) were normal. Carbohydrate deficient transferrin study, lysosomal enzymes, and 7-dehydrocholesterol level were also normal. She has not had documented hypoglycemia or hyperglycemia. Psychometric testing led to the diagnosis of mild intellectual disability. Speech and occupational therapy were provided through school and she has continued to make steady developmental progress.

91d24b08-b231-4ae2-be7d-c8b11bed2f93_figure1.gif

Figure 1. MRI findings.

(1-A) – Axial MRI FLAIR image from the affected female child done at 4.5 years of age shows hyperintensities in the periventricular (primarily periatrial) white matter (arrows). (1-B) Axial FLAIR and sagittal T1 MRI images from the affected male child at 2.5 years of age. This shows bilateral periventricular (periatrial) and subcortical white matter hyperintensities consistent with dysmyelination (arrows). Brain architecture (corpus callosum, cerebellum, and cortical gyration) was normal.

Patient 2

The second patient is a 10 year old boy who was born at 36 weeks gestation weighing 5 pounds, and developed mild neonatal jaundice. The pregnancy was complicated by oligohydramnios and decreased fetal movement. He was diagnosed with hypotonia during infancy. He too achieved motor milestones at appropriate times (walked at 15 months) but speech was delayed. He had an episode of febrile status epilepticus at 17 months, and subsequent epileptic seizures without fever. Seizures have been controlled with levetiracetam (50 mg/kg/day, corresponding to 500 mg twice daily). A recent EEG showed symmetric, bilateral, frontally dominant polyspike and wave discharges, consistent with generalized epilepsy. He has a history of recurrent pulmonary infections and reactive airway disease; initial testing by CFTR gene sequencing was not conclusive and revealed only benign variants. Sweat chloride testing was abnormal on one occasion and then borderline, pancreatic elastase was normal, and a clinical diagnosis of cystic fibrosis was made. He also had recurrent otitis media that required tympanostomy tubes.

Physical examination at age 2.5 years showed small stature (5% for height and weight) microcephaly (head circumference 3 SD below mean for age), low anterior hair line, deep set eyes with mild hypotelorism, and a normal neurological exam. His phenotype was similar to his older sister, although he seemed to be more severely affected. MRI of the brain at age 2.5 years showed extensive FLAIR/T2 hyperintensities in the periventricular and subcortical white matter (Figure 1B).

The following biochemical and genetic tests were normal: array CGH, fragile X test, TORCH titers, quantitative plasma amino acids, quantitative urine organic acids, fluorescent in-situ hybridization (FISH) test for Pelizaeus-Merzbacher disease, very long chain fatty acids, enzyme assays for CLN1 (PPT1 – palmitoyl-protein thioesterase 1) and CLN2 (TPP1-tripeptidyl-peptidase 1), and 7-dehydrocholesterol. He has not had documented hypoglycemia or hyperglycemia.

His features have remained constant on follow-up examinations, with persistent microcephaly and mild hypotelorism. He is making slow progress in school with speech, occupational and physical therapy.

Ethics

Patients and parents were enrolled into a clinical research protocol sponsored by the Translational Genomics Research Institute (TGen) approved by the Western Institutional Review Board, Protocol Number 20120789. After informed consent, blood samples were collected for DNA and RNA extraction. A separate buccal swab was sent for Sanger sequencing and independent confirmation of selected variants in a clinical laboratory (GeneDx, Gaithersberg, MD).

Exome sequencing

Libraries were prepared using the Illumina’s TruSeq DNA sample preparation kit and the TruSeq exome enrichment kit (Illumina, Inc., San Diego, CA, USA), following the manufacturer’s protocol. Sequencing was done by 100-bp paired-end sequencing on a HiSeq2000 instrument (Illumina, Inc., San Diego, CA, USA). Reads were aligned to the Human Genome (Hg19/GRC37) using Burrows-Wheeler transform alignment (BWA v.0.7.5)1. PCR duplicates were removed using Picard v.1.922, and base quality recalibration, indel realignment and single nucleotide polymorphism (SNP) and indel discovery were performed using the Genome Analysis Toolkit (GATK v.2.5-2)3. Variants were annotated with SnpEff 3.2a and selected (SnpSift) for protein-coding events. Prediction scores were loaded from dbNSFP and used for filtering.

Results

Exome sequencing identified 33,640 SNPs and indels common to the two affected individuals. The majority of these variants were common in the population, and only 4,355 were considered either novel, private or rare variants. An annotated variant file was created that included variants in any of the four family members (male child, female child, father, and mother). Excluding UTR (untranslated region) and synonymous variants left 452 candidate variants.

There were no variants consistent with de novo mutation in both children (with presumed germline mosaicism in a parent). Four variants were identified consistent with a homozygous recessive model: SERINC2, PTH2R, SGK223, and PMP22. None of these were consistent with the clinical phenotype.

We considered an X-linked recessive model (female child less severe than male) and identified variants were in NHS (Nance-Horan syndrome), DDX53, WAS, and TREX2; four variants in RPGR. The TREX2 variant has been reported in 83 hemizygotes in the ExAC Browser database v 0.3 (Broad Institute). The DDX53 variant is rare and has been implicated as a potential X-linked autism locus. X chromosome inactivation studies in the carrier mother have not been done.

When we considered compound heterozygous model, we identified only two variants in a single gene, TRMT10A. Both children have inherited a maternal variant encoding a nonsense mutation, c.277C>T (p.Arg93*) and a paternal variant encoding a nonsense mutation, c.397C>T (p.Arg133*). The Arg133* variant has been observed in one of 120,000 alleles in the ExAC Browser database, while the Arg93* allele has never been reported before. Based on the damaging nature of these mutations (protein truncation), consistency with an autosomal recessive model, and two previous reports of homozygous TRMT10A mutations in children with primary microcephaly4,5, we concluded that the TRMT10A mutations were causal for our patients’ phenotype.

Discussion

Microcephaly is a clinical condition, rather than a specific diagnosis, defined as having a small brain size, measured by head circumference. It is generally accepted that head circumference less than 2–4 standard deviations below the mean for age and gender is considered to be microcephaly6,7.

Primary microcephaly is either congenital and present at birth, or progressive and caused by postnatal decrease in head circumference growth rate (as in Rett syndrome, for instance). Congenital microcephaly occurs more frequently in patients born to consanguineous parents. Congenital microcephaly can be further classified by clinical and imaging features set forth by Barkovich and others8,9. Patients with autosomal recessive primary microcephaly (MCPH) have microcephaly at birth and non-progressive mental retardation10,11. Microcephaly with normal or simplified gyration (MSG) is thought to be a result of abnormal neuronal and glial proliferation or apoptosis12.

Many genes have been implicated in the development of microcephaly (summarized in Table 1) including ASPM, MCPH1, CDK5RAP2, CEP152, CENPJ, WDR62, STIL, CASC5, CEP135, ZNF335, PHC1, CDK6, with many of them contributing to centrosome and spindle protein dysfunction during mitosis6,10,1317. Mutations in the ASPM gene are the most common in this group, and account for 30–40 percent of these cases18. Genes implicated in primary microcephaly with associated features such as cognitive and motor impairment and epilepsy include SLC25A19, ATR, ARFGEF2, and RAB3GAP119. PYCR2 mutation described by Nakayama causes dysfunctional proline synthesis and leaves affected patients more susceptible to oxidative stress induced apoptosis, leading to postnatal microcephaly from cell death in the developing brain20.

Table 1. Genes causing microcephaly syndromes.

This table contains a summary of selected primary microcephaly syndromes, including MCPH 1–15. Information provided includes a brief description of the phenotype, gene that is mutated, and pathogenic mechanism.

SyndromePhenotypeInheritanceGeneChromosomeProtein function/
pathogenic mechanism
MCPH1
(OMIM#251200)
microcephaly, intellectual
disability, epilepsy, craniofacial
dysmorphism, growth retardation
ARMCPH18p23.1premature chromosomal
condensation; defective
G2/M checkpoint arrest,
CDK1 phosphorylation
MCPH2
(OMIM#604317)
microcephaly, simplified gyration,
cortical malformations, epilepsy,
craniofacial dysmorphism, growth
retardation
ARWDR6210q13.12localized to spindle poles
during mitosis
MCPH3
(OMIM#604804)
microcephaly, intellectual
disability, simplified gyration,
developmental and psychomotor
delay, cortical malformations,
craniofacial dysmorphism,
hypotonia
ARCDK5RAP29q33.2centrosomal function and
spindle orientation
MCPH4
(OMIM#604321)
microcephaly, intellectual disability,
growth retardation
ARCASC515q15.1kinetochore protein,
centromere attachment to
microtubules, and spindle-
assembly checkpoint
signaling
MCPH5
(OMIM#6-8716)
microcephaly, simplified gyration,
cortical malformations, intellectual
disability
ARASPM1q31.3abnormal spindle gene;
mitotic spindle function
in neuroblasts, cleavage
plane alteration, asymmetric
division
MCPH6
(OMIM#608393)
microcephaly, severe intellectual
disability, craniofacial
dysmorphism, epilepsy, joint
stiffness
ARCENPJ13q12.12centromeric protein J,
microtubule assembly and
nucleation
MCPH7
(OMIM#612703)
microcephaly, intellectual
disability, short stature,
strabismus, ataxia, epilepsy,
T cell ALL
ARSTIL1p33neuronal cell proliferation;
nuclear localization signal of
TGF beta
MCPH8
(OMIM#614673)
microcephaly, craniofacial
dysmorphism
ARCEP1354q12fragmented centrosomes,
disorganized microtubules
MCPH9
(OMIM#614852)
microcephaly, simplified gyration,
psychomotor delay, jerky
movements, mirror movements
ARCEP15215q21.1centrosomal core protein
MCPH10
(OMIM#615095)
microcephaly, simplified
gyration, cortical malformation,
delayed myelination, craniofacial
dysmorphism, hypertonia,
spasticity
ARZNF33520q13.12zinc finger protein;
neurogenesis, neuronal
differentiation
MCPH11
(OMIM#615414)
microcephaly, intellectual
disability, short stature
ARPHC112p13.31polycomb repressor
complex; ubiquitination,
proteosome-mediated
degradation, chromatin
remodeling
MCPH12
(OMIM#616080)
microcephaly, intellectual
disability, simplified gyral pattern,
craniofacial dysmorphism
ARCDK67q21.2cyclin dependent kinase, cell
cycle regulation; microtubule
orientation and organization
MCPH13
(OMIM#616051)
microcephaly, simplified gyration,
IUGR, craniofacial dysmorphism,
short stature, psychomotor
delay, absent speech, spasticity,
osteopenia
ARCENPE4q24kinetochore associated
motor protein
MCPH14
(OMIM#616402)
microcephaly, severe intellectual
disability, speech delay,
aggressive behavior, epilepsy,
cortical malformation
ARSASS61p21.2centrosome duplication,
spindle assembly; impaired
centriole formation
MCPH15
(OMIM#616486)
microcephaly, severe intellectual
disability, psychomotor
delay, spastic quadriparesis,
hyperreflexia, hypotonia, epilepsy,
cortical malformations, early death
ARMFSD2A1p34.2uptake of long chain fatty
acids
Mental
retardation, AD 32
(OMIM#616268)
microcephaly, developmental
delay, craniofacial dysmorphism,
cardiac defects, ocular anomalies
ADKAT6A8p11.21histone acetyltransferse;
dysregulation of chromatin
modification
Mental retardation,
AR 5 (OMIM#611091)
microcephaly, severe intellectual
disability, craniofacial
dysmorphism, short stature,
hypertonia
ARNSUN25q15.31trna methyltransferase;
spindle assembly during
mitosis and chromosome
segregation
Hypomyelinating
leukodystrophy 10
(OMIM#616420)
microcephaly, hypomyelination,
severe motor and speech delay,
craniofacial dysmorphism,
hypertonia
ARPYCR21q42.12pyrroline-5-carboxylate
reductase; dysfunctional
proline biosynthesis,
oxidative stress-induced
apoptosis
TAR
(thrombocytopenia
absent radius)
syndrome
(OMIM#274000)
severe microcephaly, defective
neurogenesis, thrombocytopenia-
absent radius
ARRBM8A1q21.1exon-junction complex;
rna metabolism in cortical
development, neuronal
apoptosis
Primary ciliary
dyskinesia 31
(OMIM#616369)
microcephaly, gestational demise,
craniofacial dysmorphism, renal
abnormality
ARCENPF1q41kinetochore and spindle;
microtubule regulation,
ciliogenesis
Microcephaly and
chorioretinopathy - 2
(OMIM#616171)
microcephaly, severe intellectual
disability, dwarfism, retinopathy
ARPLK44q28.2Polo-like kinase, regulator of
centriole biogenesis
Wolcott-Rallison
syndrome
(OMIM#226980)
microcephaly, simplified gyration,
infantile diabetes
AREIF2AK32p11.2serine/threonine kinase;
unfolded protein response,
ER stress-induced apoptosis
Microcephaly,
epilepsy,
diabetes-MEDS
(OMIM#614231)
microcephaly, simplified gyration,
epilepsy, infantile diabetes
ARIER3IP118q21.1Immediate early response
interacting protein; unfolded
protein response, ER stress-
induced apoptosis
microcephaly,
short stature,
impaired glucose
metabolism-MSSGM
(OMIM#616033)
microcephaly, intellectual
disability, short stature, adolescent
onset diabetes
ARTRMT10A4q23trna methyltransferase; ER
stress-induced apopotosis

Primary microcephaly is a result of a defect in the generation of the appropriate number of neurons during early neural development. Cell division of neural progenitors in the neuroepithelium can be symmetric (generating two progenitors) or asymmetric (generating one progenitor and one post-mitotic neuron). Microcephaly has been associated with microtubule, centrosome, and mitotic dysfunction. Dysfunction in the mitotic machinery may cause inappropriate asymmetric cell division during neurogenesis in the developing cortex and subventricular zone21,22. Abnormal control of apoptosis during the neurogenesis phase of development can also lead to microcephaly. Studies in mice have demonstrated microcephaly due to an increase in neuronal apoptosis and depletion of the neural progenitor population23. Specifically, endoplasmic reticulum stress-induced apoptosis has been shown to cause microcephaly and early onset diabetes from beta cell ER stress-induced apoptosis.

TRMT10A and microcephaly

TRMT10A (also known as RG9MTD2 – RNA (guanine 9)-methyltransferase domain-containing protein 2) is homologous to a yeast tRNA methyltransferase (Trm10) and methylates tRNAs at the m1G9 position. TRMT10A is expressed in several tissues (liver, kidney, spleen, lung, fat) but at especially high levels in brain and pancreatic islet cells4. Mutation of another tRNA methyltransferases, NSUN2, has been associated with microcephaly, short stature, intellectual disability, and facial dysmorphism24,25.

There are two previous reports of patients with homozygous nonsense or missense mutation of TRMT10A resulting in microcephaly. In the first report, Igoillo-Esteve and colleagues described 3 siblings, from a large consanguineous Moroccan family, with microcephaly, intellectual disability, short stature, and early-onset diabetes4. Whole exome sequencing identified a homozygous p. Arg127* nonsense mutation in the TRMT10A gene in the 3 affected patients; both parents and an unaffected brother were heterozygous for this mutation. Features in the oldest patient (at age 26), in addition to microcephaly and intellectual disability, included short stature, absence seizures, development of diabetes at age 22, and a variety of dysmorphic features. Brain MRI showed normal architecture and gyration. The other two children developed diabetes at age 19 and 14 respectively. The TRMT10A Arg127* mutation resulted in greatly reduced mRNA levels (presumably by nonsense-mediated decay) and absent protein levels. Loss of TRMT10A protein induced apoptosis in rat β-cells and increased stress-induced apoptosis by many endogenous molecules including high levels of glucose4.

In a second report, Gillis and colleagues described 3 siblings (one female and two male) born to healthy, non-consanguineous parents from a small, inbred Jewish community of Uzbekistan5. All 3 patients suffered from microcephaly, intellectual disability, short stature, seizures, and altered glucose metabolism. The female child had delayed pubertal development and was amenorrheic at age 19 years. Exome sequencing in one affected patient followed by targeted genotyping in the rest of the family (parents, two affected sibs and 9 unaffected sibs) defined a homozygous p. Gly206Arg missense mutation in TRMT10A as causing disease in this family. All three affected patients had episodes of hypoglycemia, hyperinsulinemia, and abnormal response to glucose. Brain imaging in two of these patients was normal. The Gly206Arg mutation resulted in almost complete loss of methyltransferase activity5. This suggested that decrease in methylated tRNA is responsible for growth failure, developmental delay and impaired glucose metabolism.

TRMT10A microcephaly, in contrast to primary microcephaly linked to centrosome and spindle function during mitosis, is likely related to the loss of brain volume due to increased apoptosis. TRMT10A deficiency increases the amount of beta cell apoptosis, and presumably neuronal apoptosis. The development of diabetes and abnormal glucose response may be related to endoplasmic reticulum stress-induced apoptosis induced by endogenous fatty acids and high levels of glucose4. Endoplasmic reticulum stress-induced apoptosis has also been implicated in a syndrome of primary microcephaly associated with simplified gyral pattern, epilepsy, and infantile diabetes caused by mutation of the IER3IP1 gene19.

Here we report two additional patients with primary (congenital) microcephaly and intellectual disability caused by compound heterozygous nonsense mutations of TRMT10A. These patients have not displayed hypoglycemia nor early onset diabetes. Brain imaging did show abnormalities in the central white matter, suggesting delayed or abnormal myelination. TRMT10A is not currently included in microcephaly gene panels available from commercial laboratories, stressing the importance of exome sequencing in the genetic diagnosis of primary microcephaly. The correct genetic diagnosis in our patients allows for anticipation and early treatment of medical complications by institution of meticulous glucose monitoring and control from an early age.

Consent

Written informed consent for publication of their clinical details and clinical images was obtained from the parent of the patients.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 28 Sep 2015
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Narayanan M, Ramsey K, Grebe T et al. Case Report: Compound heterozygous nonsense mutations in TRMT10A are associated with microcephaly, delayed development, and periventricular white matter hyperintensities [version 1; peer review: 2 approved]. F1000Research 2015, 4:912 (https://doi.org/10.12688/f1000research.7106.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 28 Sep 2015
Views
16
Cite
Reviewer Report 19 Oct 2015
Ganeshwaran H. Mochida, Pediatric Neurology Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA 
Approved
VIEWS 16
This paper describes two siblings with microcephaly and developmental delay, who were found to have compound heterozygous variants in the TRMT10A gene. Biallelic mutations of TRMT10A have recently been reported in individuals with microcephaly and abnormalities in glucose homeostasis. Seeing ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Mochida GH. Reviewer Report For: Case Report: Compound heterozygous nonsense mutations in TRMT10A are associated with microcephaly, delayed development, and periventricular white matter hyperintensities [version 1; peer review: 2 approved]. F1000Research 2015, 4:912 (https://doi.org/10.5256/f1000research.7652.r10547)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
21
Cite
Reviewer Report 13 Oct 2015
Gihan Tennekoon, Department of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA 
Approved
VIEWS 21
TRMT10A is an tRNA (guanine) methyltransferase that is highly expressed in the pancreatic islet cells and brain. In the brain it appears expression occurs early during gestation and expression is in the dorsal telencephalon with high expression in the ventricular ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Tennekoon G. Reviewer Report For: Case Report: Compound heterozygous nonsense mutations in TRMT10A are associated with microcephaly, delayed development, and periventricular white matter hyperintensities [version 1; peer review: 2 approved]. F1000Research 2015, 4:912 (https://doi.org/10.5256/f1000research.7652.r10548)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 28 Sep 2015
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.